However, recently DJ-1 has emerged as a significant biomarker since its presence has been detected in the serum of gastric cancer [99], prostate carcinomas [100], pancreatic cancer [101], non-small cell lung cancer [102] and uveal melanoma [103] patients. Here, PARK7 is linked to prostate carcinoma.